Cited by 298Antifungal resistance and susceptibilityFungal Plant Pathogen ControlFungal Infections and Studies

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi

Open access

Cuenca-Estrella, Manuel, Gomez-Lopez, Alicia, Mellado, Emilia, Buitrago, Maria J., Monzon, Araceli, Rodriguez-Tudela, Juan Luis·2006·Antimicrobial Agents and Chemotherapy

DOI 10.1128/aac.50.3.917-921.2006PMC PMC1426453

Open this paper in CoChat — free account

Abstract

We have compared the activities of posaconazole and other currently available antifungal agents against a collection of 3,378 clinical isolates of yeasts and filamentous fungi. A total of 1,997 clinical isolates of Candida spp., 359 of other yeast species, 697 strains of Aspergillus spp., and 325 nondermatophyte non- Aspergillus spp. were included. The average geometric means of the MICs of agents that were tested against Candida spp. were 0.23 μg/ml for amphotericin B, 0.29 μg/ml for flucytosine, 0.97 μg/ml for fluconazole, 0.07 μg/ml for itraconazole, 0.04 μg/ml for voriconazole, 0.15 μg/ml for caspofungin, and 0.03 μg/ml for posaconazole. Voriconazole and posaconazole were active in vitro against the majority of isolates, with resistance to fluconazole and itraconazole, and against Cryptococcus neoformans and other Basidiomycota yeasts. Posaconazole was the most active of antifungal agents tested against Aspergillus spp., with an average geometric mean of 0.10 μg/ml. It was active against Paecilomyces spp., Penicillium spp., Scedosporium apiospermum , and some black fungi, such as Alternaria spp. Multiresistant filamentous fungi, such as Scedosporium prolificans , Scopulariopsis brevicaulis , and Fusarium solani , were also resistant to voriconazole, caspofungin, and posaconazole. Amphotericin B and posaconazole were found to be active against most of the Mucorales strains tested. Posaconazole and currently available antifungal agents exhibit a potent activity in vitro against the majority of pathogenic fungal species.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1128/aac.50.3.917-921.2006

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · PEDIATRICS · doi:10.1542/peds.65.1.187 · Cited by 14,736
Antifungal Activities of Posaconazole, Ravuconazole, and Voriconazole Compared to Those of Itraconazole and Amphotericin B against 239 Clinical Isolates of Aspergillus spp. and Other Filamentous Fungi: Report from SENTRY Antimicrobial Surveillance Program, 2000
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.4.1032-1037.2002 · Cited by 405
Activities of Caspofungin, Itraconazole, Posaconazole, Ravuconazole, Voriconazole, and Amphotericin B against 448 Recent Clinical Isolates of Filamentous Fungi
Diekema, D. J., Messer, S. A., Hollis, R. J., Jones, R. N., & Pfaller, M. A. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.8.3623-3626.2003 · Cited by 370
Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults
Courtney, R., Wexler, D. B., Radwanski, E., Lim, J. M., & Laughlin, M. A. (2003) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01977.x · Cited by 328
In vitro susceptibilities of zygomycetes to conventional and new antifungals
Dannaoui, É. (2002) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg020 · Cited by 312
Experimental Pulmonary Aspergillosis Due toAspergillus terreus:Pathogenesis and Treatment of an Emerging Fungal Pathogen Resistant to Amphotericin B
Walsh, T. J., Petraitis, V., Petraitienė, R., Field‐Ridley, A., Sutton, D. A., Ghannoum, M. A., Sein, T., Schaufele, R. L., Peter, J., Bacher, J. D., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/377210 · Cited by 252
Untitled work
(2003) · PubMed · Cited by 240
Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection
Denning, D. W. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.3.401 · Cited by 234
In Vitro Activities of New and Conventional Antifungal Agents against ClinicalScedosporiumIsolates
Meletiadis, J., Meis, J. F. G. M., Mouton, J. W., Rodriquez-Tudela, J. L., Donnelly, J. P., Verweij, P. E., & the EUROFUNG Network (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.62-68.2002 · Cited by 232
Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum
Cuenca‐Estrella, M., Ruiz-Dı́ez, B., Martı́nez-Suárez, J. V., Monzón, A., & Rodrı́guez-Tudela, J. L. (1999) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/43.1.149 · Cited by 211
Self-citation

Flagged first, then by citations

Show all 32 references

1 of the 32 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Keating, G. M. 2006. Posaconazole. Drugs65:1553-1567.

Sorted by citations

Items 101–200 of 298

Galactomannan detection in Geotrichum capitatum invasive infections: report of 2 new cases and review of diagnostic options
Bonini, A., Capatti, C., Parmeggiani, M., Gugliotta, L., Micozzi, A., Gentile, G., Capria, S., & Girmenia, C. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.08.008 · Cited by 47
Process Analysis of Variables for Standardization of Antifungal Susceptibility Testing of Nonfermentative Yeasts
Zaragoza, Ó., Mesa-Arango, A. C., Gómez‐López, A., Bernal‐Martínez, L., Rodrı́guez-Tudela, J. L., & Cuenca‐Estrella, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01631-10 · Cited by 49
Self-citation
Role of Aspergillus lentulus 14-α Sterol Demethylase (Cyp51A) in Azole Drug Susceptibility
Mellado, E., Alcázar‐Fuoli, L., Cuenca‐Estrella, M., & Rodrı́guez-Tudela, J. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05178-11 · Cited by 46
Self-citation
Multiple Scedosporium apiospermum abscesses in a woman survivor of a tsunami in northeastern Japan: a case report
Nakamura, Y., Utsumi, Y., Suzuki, N., Nakajima, Y., Murata, O., Sasaki, N., Nitanai, H., Nagashima, H., Miyamoto, S., Yaegashi, J., et al. (2011) · Journal of Medical Case Reports · doi:10.1186/1752-1947-5-526 · Cited by 44
Posaconazole: a new broad-spectrum antifungal agent
Kwon, D. S., & Mylonakis, E. E. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.8.1167 · Cited by 44
Posaconazole
Frampton, J. E., & Scott, L. J. (2008) · Drugs · doi:10.2165/00003495-200868070-00008 · Cited by 43
Scedosporium prolificans: an emerging pathogen in France?
Grenouillet, F., Botterel, F., Crouzet, J., Larosa, F., Hicheri, Y., Forel, J., Hélias, P., Ranque, S., & Delhaes, L. (2009) · Medical Mycology · doi:10.1080/13693780802454761 · Cited by 47
Scedosporiosis in patients with acute leukemia: a retrospective multicenter report
Caira, M., Girmenia, C., Valentini, C. G., Sanguinetti, M., Bonini, A., Rossi, G., Fianchi, L., Leone, G. G. M., & Pagano, L. (2007) · Haematologica · doi:10.3324/haematol.11740 · Cited by 42
In Vitro Antifungal Susceptibility of Clinically Relevant Species Belonging to Aspergillus Section Flavi
Gonçalves, S. S., Stchigel, A. M., Cano, J., Guarro, J., & Colombo, A. L. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01902-12 · Cited by 41
HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases
Müller, C., Arndt, M., Queckenberg, C., Cornely, O. A., & Theisohn, M. (2006) · Mycoses · doi:10.1111/j.1439-0507.2006.01297.x · Cited by 41
Posaconazole in the management of refractory invasive fungal infections
Neumeister, P. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s3329 · Cited by 40
Mucormycosis Amid COVID-19 Crisis: Pathogenesis, Diagnosis, and Novel Treatment Strategies to Combat the Spread
Dogra, S., Arora, A., Aggarwal, A., Passi, G., Sharma, A., Singh, G., & Barnwal, R. P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.794176 · Cited by 40
Role of antifungal susceptibility testing in patient management
Forrest, G. N. (2006) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e328010682c · Cited by 39
Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy
Cornely, O. A., Aversa, F., Cook, P., Jones, B., Michallet, M., Shea, T. C., & Vallejo, C. T. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01682.x · Cited by 40
Genotyping of Fusarium Isolates from Onychomycoses in Colombia: Detection of Two New Species Within the Fusarium solani Species Complex and In Vitro Antifungal Susceptibility Testing
Guevara‐Suarez, M., Cano, J., de García, M. C. C., Sopó, L., de BEDOUT, C., Cano, L. E., Garcı́a, A. M., Motta, A., Amézquita, A., Cárdenas, M. E., et al. (2016) · Mycopathologia · doi:10.1007/s11046-016-9983-9 · Cited by 39
Antibiofilm activity of carboxymethyl chitosan on the biofilms of non-Candida albicans Candida species
Tan, Y., Leonhard, M., Moser, D., & Schneider‐Stickler, B. (2016) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2016.04.101 · Cited by 39
Development, optimization and characterization of nanoemulsion loaded with clove oil-naftifine antifungal for the management of tinea
Alghaith, A. F., Alshehri, S., Alhakamy, N. A., & Hosny, K. M. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1879314 · Cited by 38
Voriconazole-Resistant Penicillium oxalicum: An Emerging Pathogen in Immunocompromised Hosts
Chowdhary, A., Kathuria, S., Agarwal, K., Sachdeva, N., Singh, P. K., Jain, S., & Meis, J. F. G. M. (2014) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofu029 · Cited by 38
Antifungal activity againstScedosporiumspecies and novel assays to assess antifungal pharmacodynamics against filamentous fungi
Wiederhold, N. P., & Lewis, R. E. (2008) · Medical Mycology · doi:10.1080/13693780802510224 · Cited by 37
Treatment With Intrastromal and Intracameral Voriconazole in 2 Eyes With Lasiodiplodia theobromae Keratitis
Lekhanont, K., Nonpassopon, M., Nimvorapun, N., & Santanirand, P. (2015) · Medicine · doi:10.1097/md.0000000000000541 · Cited by 35
Breakthrough Disseminated Scedosporium prolificans Infection in a Patient with Relapsed Leukaemia on Prolonged Voriconazole Followed by Posaconazole Prophylaxis
Ananda-Rajah, M. R., Grigg, A., & Slavin, M. A. (2008) · Mycopathologia · doi:10.1007/s11046-008-9131-2 · Cited by 35
Detection of Caspofungin Resistance in Candida spp. by Etest
Desnos‐Ollivier, M., Dromer, F., & Dannaoui, É. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.00053-08 · Cited by 35
Effectiveness of Posaconazole in Recalcitrant Fungal Keratitis Resistant to Conventional Antifungal Drugs
Altun, A., Kurna, S. A., Şengör, T., Altun, G., Olcaysü, O. O., Akı, S. F., & Şimşek, M. (2014) · Case Reports in Ophthalmological Medicine · doi:10.1155/2014/701653 · Cited by 34
Phylogenetic Relationships Matter: Antifungal Susceptibility among Clinically Relevant Yeasts
Schmalreck, A., Lackner, M., Becker, K., Fegeler, W., Czaika, V. A., Ulmer, H., & Lass‐Flörl, C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01799-13 · Cited by 34
Bloodstream Infections Caused by Magnusiomyces capitatus and Magnusiomyces clavatus : Epidemiological, Clinical, and Microbiological Features of Two Emerging Yeast Species
Noster, J., Koeppel, M. B., Desnos‐Ollivier, M., Aigner, M., Bader, O., Dichtl, K., Göttig, S., Haas, A., Kurzai, O., Pranada, A. B., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01834-21 · Cited by 33
The Epidemiology of Invasive Candidiasis
Pfaller, M. A., & Diekema, D. J. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch29 · Cited by 33
Treatment of Fungal Peritonitis with a Combination of Intravenous Amphotericin B and Oral Flucytosine, and Delayed Catheter Replacement in Continuous Ambulatory Peritoneal Dialysis
Wong, P.-N., Lo, K., Tong, G. M. W., Chan, S., Lo, M., Mak, S., & Wong, A. K. (2008) · Peritoneal Dialysis International · doi:10.1177/089686080802800211 · Cited by 33
Lodderomyces elongisporus endocarditis in an intravenous drug user: a new entity in fungal endocarditis
Daveson, K., & Woods, M. L. (2012) · Journal of Medical Microbiology · doi:10.1099/jmm.0.047548-0 · Cited by 31
Detection of invasive infection caused byFusarium solaniand non-Fusarium solanispecies using a duplex quantitative PCR-based assay in a murine model of fusariosis
Bernal‐Martínez, L., Buitrago, M. J., Castelli, M. V., Rodrı́guez-Tudela, J. L., & Cuenca‐Estrella, M. (2012) · Medical Mycology · doi:10.3109/13693786.2011.604047 · Cited by 31
Self-citation
Aspergillus viridinutans: an agent of adult chronic invasive aspergillosis
Coelho, D., Silva, S. P., Vale-Silva, L. A., Gomes, H. C., Pinto, E., Sarmento, A., & Pinheiro, M. D. (2011) · Medical Mycology · doi:10.3109/13693786.2011.556672 · Cited by 31
Concomitant cases of disseminatedGeotrichum clavatuminfections in patients with acute myeloid leukemia
Picard, M., Cassaing, S., Letocart, P., Verdeil, X., Protin, C. A., Chauvin, P., Iriart, X., Cavalié, L., Valentin, A., Marchou, B., et al. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.820290 · Cited by 31
New and Investigational Triazole Agents for the Treatment of Invasive Fungal Infections
Sarro, A. D., Camera, E. L., & Fera, M. T. (2008) · Journal of Chemotherapy · doi:10.1179/joc.2008.20.6.661 · Cited by 30
Antifungal susceptibility of clinical Candida parapsilosis isolates in Kuwait
Asadzadeh, M., Al‐Sweih, N., Ahmad, S., & Khan, Z. U. (2008) · Mycoses · doi:10.1111/j.1439-0507.2008.01492.x · Cited by 30
Single‐dose pharmacokinetics of ceftazidime and fluconazole during concurrent clinical use in cold‐stunned Kemp’s ridley turtles (Lepidochelys kempii)
Innis, C. J., Ceresia, M. L., Merigo, C., Weber, E. S., & Papich, M. G. (2011) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2011.01290.x · Cited by 30
In Vitro Susceptibilities of Invasive Isolates of Candida Species: Rapid Increase in Rates of Fluconazole Susceptible-Dose Dependent Candida glabrata Isolates
Ruan, S., Chu, C., & Hsueh, P. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00323-08 · Cited by 28
Fatal Cases of Bloodstream Infection by Fusarium solani and Review of Published Literature
Dabas, Y., Bakhshi, S., & Xess, I. (2015) · Mycopathologia · doi:10.1007/s11046-015-9960-8 · Cited by 29
Clinical relevance of resistance to antifungals
Rodrı́guez-Tudela, J. L., Alcázar‐Fuoli, L., Cuesta, I., Alastruey‐Izquierdo, A., Monzón, A., Mellado, E., & Cuenca‐Estrella, M. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(08)70010-4 · Cited by 29
Self-citation
In Vitro Activities of a Wide Panel of Antifungal Drugs against Various Scopulariopsis and Microascus Species
Skóra, M., Bulanda, M., & Jagielski, T. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00978-15 · Cited by 28
Posaconazole for the treatment of mucormycosis
Enoch, D., Aliyu, S. H., Sule, O., Lewis, S. J., & Karas, J. A. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.05.010 · Cited by 28
Does a triple combination have better activity than double combinations against multiresistant fungi? Experimental in vitro evaluation
Martín‐Vicente, A., Guarro, J., & Capilla, J. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.12.015 · Cited by 27
Isolation of Rhodotorula mucilaginosa from blood cultures in a tertiary care hospital
Falces‐Romero, I., Cendejas‐Bueno, E., Romero‐Gómez, M. P., & García‐Rodríguez, J. (2017) · Mycoses · doi:10.1111/myc.12703 · Cited by 27
Infections caused by Scedosporium/Lomentospora species: Clinical and microbiological findings in 21 cases
Cobo, F., Lara-Oya, A., Rodríguez‐Granger, J., Sampedro, A., Aliaga–Martínez, L., & Navarro‐Marí, J. M. (2017) · Medical Mycology · doi:10.1093/mmy/myx147 · Cited by 27
In Vitro Triple Combination of Antifungal Drugs against Clinical Scopulariopsis and Microascus Species
Yao, L., Wan, Z., Li, R., & Yu, J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00145-15 · Cited by 27
Synthesis and antimicrobial activities of His(2-aryl)-Arg and Trp-His(2-aryl) classes of dipeptidomimetics
Mahindra, A., Sharma, K. K., Rathore, D., Khan, S. I., Jacob, M. R., & Jain, R. (2014) · MedChemComm · doi:10.1039/c4md00041b · Cited by 27
Pharmacotherapy of yeast infections
Gómez‐López, A., Zaragoza, Ó., Rodríguez-Tudela, J. L., & Cuenca‐Estrella, M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.16.2801 · Cited by 29
Self-citation
A Mini Review of Candida Species in Hospital Infection: Epidemiology,Virulence Factor and Drugs Resistance and Prophylaxis
Pitangui, N. D. S. (2013) · Tropical Medicine & Surgery · doi:10.4172/2329-9088.1000141 · Cited by 26
In vitro activities of eight antifungal drugs against 70 clinical and environmental isolates of Alternaria species
Badali, H., de Hoog, S., Curfs-Breuker, I., Andersen, B., & Meis, J. F. G. M. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp109 · Cited by 27
Three-dimensional models of 14α-sterol demethylase (Cyp51A) from Aspergillus lentulus and Aspergillus fumigatus: an insight into differences in voriconazole interaction
Alcázar‐Fuoli, L., Cuesta, I., Rodrı́guez-Tudela, J. L., Cuenca‐Estrella, M., Sanglard, D., & Mellado, E. (2011) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2011.06.005 · Cited by 26
Self-citation
Aspergillus otitis in small animals – a retrospective study of 17 cases
Goodale, E. C., Outerbridge, C. A., & White, S. D. (2015) · Veterinary Dermatology · doi:10.1111/vde.12283 · Cited by 26
Isolation of Exophiala dermatitidis from pigmented sputum in a cystic fibrosis patient
Griffard, E. A., Guajardo, J. R., Cooperstock, M. S., & Scoville, C. L. (2010) · Pediatric Pulmonology · doi:10.1002/ppul.21187 · Cited by 26
Activities of fluconazole and voriconazole against bloodstream isolates of Candida glabrata and Candida krusei: a 14-year study in a Spanish tertiary medical centre
Quindós, G., Sánchez-Vargas, L. O., Villar-Vidal, M., Eraso, E., Alkorta, M., & Hernández-Almaraz, J. L. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.09.010 · Cited by 26
In vitro antifungal activity of aminosterols against moulds isolated from cystic fibrosis patients
Alhanout, K., Brunel, J. M., Ranque, S., & Rolain, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq089 · Cited by 25
Frequency of Voriconazole Resistance In Vitro among Spanish Clinical Isolates of Candida spp. According to Breakpoints Established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing
Cuenca‐Estrella, M., Gómez‐López, A., Cuesta, I., Zaragoza, Ó., Mellado, E., & Rodríguez-Tudela, J. L. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01757-10 · Cited by 25
Self-citation
Disseminated Scedosporium prolificans infection in an ‘extensive metaboliser’: navigating the minefield of drug interactions and pharmacogenomics
Trubiano, J. A., Paratz, E. D., Wolf, M., Teh, B. W., Todaro, M., Thursky, K., & Slavin, M. A. (2014) · Mycoses · doi:10.1111/myc.12199 · Cited by 25
Infections caused by non- Candida , non- Cryptococcus yeasts
Pfaller, M. A., Diekema, D. J., & Merz, W. G. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00010-4 · Cited by 25
In Vitro Susceptibility to Posaconazole of 1,903 Yeast Isolates Recovered in France from 2003 to 2006 and Tested by the Method of the European Committee on Antimicrobial Susceptibility Testing
Lortholary, O., Dannaoui, É., Raoux‐Barbot, D., Hoinard, D., Datry, A., Paugam, A., Poirot, J.-L., Lacroix, C., & Dromer, F. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00496-07 · Cited by 25
Voriconazole: A Broad Spectrum Triazole for the Treatment of Serious and Invasive Fungal Infections
Maschmeyer, G., & Haas, A. (2006) · Future Microbiology · doi:10.2217/17460913.1.4.365 · Cited by 24
The epidemiology of fungal infections
Lockhart, S. R., Diekema, D. J., & Pfaller, M. A. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00001-3 · Cited by 24
Breakthrough pulmonary Aspergillus fumigatus infection with multiple triazole resistance in a Spanish patient with chronic myeloid leukemia
Mellado, E., de la Cámara, R., Buendía, B., Rodrı́guez-Tudela, J. L., & Cuenca‐Estrella, M. (2012) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2012.09.002 · Cited by 23
Self-citation
Amphotericin B and voriconazole susceptibility profiles for the Fusarium solani species complex: comparison between the E-test and CLSI M38-A2 microdilution methodology
Debourgogne, A., de Hoog, S., Lozniewski, A., & Machouart, M. (2011) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-011-1323-x · Cited by 23
The use of caspofungin in HIV-infected individuals
Waters, L. J., & Nelson, M. R. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.6.899 · Cited by 23
Evaluation of the New Micronaut- Candida System Compared to the API ID32C Method for Yeast Identification
Szabó, Z., Tóth, B., Kovács, M., Kardos, G., Maráz, A., Rozgonyi, F., & Majoros, L. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02350-07 · Cited by 22
Assessment of occupational exposure to azole resistant fungi in 10 Portuguese bakeries
Caetano, L. A., Faria, T., Batista, A. C. L., Viegas, S., & Viegas, C. S. B. (2017) · AIMS Microbiology · doi:10.3934/microbiol.2017.4.960 · Cited by 21
Plasma Concentrations and Safety Assessment of Voriconazole in Red-Eared Slider Turtles (Trachemys scripta elegans) after Single and Multiple Subcutaneous Injections
Innis, C. J., Young, D., Wetzlich, S. E., Whitcomb, A. J., & Tell, L. A. (2014) · Journal of Herpetological Medicine and Surgery · doi:10.5818/1529-9651-24.1.28 · Cited by 20
In vitro interactions of itraconazole and micafungin against clinically important filamentous fungi
Ruíz-Cendoya, M., Rodríguez, M. M., Mariné, M., Pastor, F., & Guarro, J. (2008) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2008.05.015 · Cited by 20
Primary subcutaneousAlternaria alternatainfection of the hand in an immunocompromised host
Kpodzo, D. S., Calderwood, M. S., Ruchelsman, D. E., Abramson, J. S., Piris, A., Winograd, J. M., & Kotton, C. N. (2011) · Medical Mycology · doi:10.3109/13693786.2011.555848 · Cited by 20
Novel Penicillium species causing disseminated disease in a Labrador Retriever dog
Rothacker, T. R., Jaffey, J. A., Rogers, E. R., Fales, W. H., Gibas, C. F. C., Wiederhold, N. P., Sanders, C. J., Mele, J., Fan, H., Cohn, L. A., et al. (2020) · Medical Mycology · doi:10.1093/mmy/myaa016 · Cited by 21
Hyalohyphomycosis
Nucci, M., & Anaissie, E. J. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-5680-5.00013-x · Cited by 20
Design of Two Alternative Routes for the Synthesis of Naftifine and Analogues as Potential Antifungal Agents
Abonı́a, R., Garay, A., Castillo, J., Braulio Insuasty, O., Jairo Quiroga, P., Nogueras, M., Cobo, J., Butassi, E., & Zacchino, S. A. (2018) · Molecules · doi:10.3390/molecules23030520 · Cited by 19
Chronic aspergillus infections of the respiratory tract: diagnosis, management and antifungal resistance
Izumikawa, K., Takazono, T., & Kohno, S. (2010) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32833ed694 · Cited by 19
Crossover between the control of fungal pathogens in medicine and the wider environment, and the threat of antifungal resistance
Gisi, U. (2021) · Plant Pathology · doi:10.1111/ppa.13429 · Cited by 18
Antifúngicos de uso sistémico
Quiles‐Melero, I., & García‐Rodríguez, J. (2021) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2021.04.004 · Cited by 18
In vitro antifungal susceptibility of Scopulariopsis brevicaulis isolates
Skóra, M., Macura, A. B., & Bulanda, M. (2014) · Medical Mycology · doi:10.1093/mmy/myu039 · Cited by 18
Prenylated Trans-Cinnamic Esters and Ethers against Clinical Fusarium spp.: Repositioning of Natural Compounds in Antimicrobial Discovery
Oufensou, S., Casalini, S., Balmas, V., Carta, P., Chtioui, W., Dettori, M. A., Fabbri, D., Migheli, Q., & Delogu, G. (2021) · Molecules · doi:10.3390/molecules26030658 · Cited by 17
Otomycosis due to Aspergillus spp. in a dog: case report and literature review
Coyner, K. S. (2010) · Veterinary Dermatology · doi:10.1111/j.1365-3164.2010.00903.x · Cited by 17
Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan
Lin, C., Liu, C.-P., Hsieh, F.-C., Lee, C.-M., & Wang, W.-S. (2014) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2014.07.007 · Cited by 17
Successful Use of Fosmanogepix for Treatment of Rare Highly Resistant Cutaneous Fusariosis in a Pediatric Patient With STAT3 Hyper-Immunoglobulin E Syndrome and End-Stage Kidney Disease
Goggin, K. P., Londeree, J., Freeman, A. F., Garro, R., & George, R. P. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad285 · Cited by 16
Antifúngicos para uso sistémico
Ruíz-Camps, I., & Cuenca‐Estrella, M. (2009) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2009.04.001 · Cited by 17
Self-citation
Tratamiento de las infecciones fúngicas en pacientes con neoplasias hematológicas
Mensa, J., de la Cámara, R., Carreras, E., Estrella, M. C., Rodríguez, J. Á. G., Gobernado, M., Picazo, J., Aguado, J. M., & Sanz, M. Á. (2009) · Medicina Clínica · doi:10.1016/j.medcli.2009.01.008 · Cited by 16
Uncommon Yeasts and Molds Causing Human Disease
Shoff, C. J., & Perfect, J. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-809633-8.21023-6 · Cited by 16
American Society of Transplantation and Cellular Therapy Series: #8-Management and Prevention of Non-Aspergillus Molds in Hematopoietic Cell Transplantation Recipients
Douglas, A. P., Lamoth, F., John, T. M., Groll, A. H., Shigle, T. L., Papanicolaou, G. A., Chemaly, R. F., Carpenter, P. A., Dadwal, S., Walsh, T. J., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.01.892 · Cited by 15
Differences in Efficacy and Cytokine Profiles following Echinocandin or Liposomal Amphotericin B Monotherapy or Combination Therapy for Murine Pulmonary or Systemic Aspergillus flavus Infections
Olson, J. A., Schwartz, J., Hahka, D., George, A., Proffitt, R. T., & Adler‐Moore, J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00607-11 · Cited by 15
Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients
Almyroudis, N. G., & Segal, B. H. (2010) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.10.141 · Cited by 15
Evaluation of Etest Performed in Mueller–Hinton Agar Supplemented with Glucose for Antifungal Susceptibility Testing of Clinical Isolates of Filamentous Fungi
Pinto, E., Lago, M., Branco, L., Vale-Silva, L. A., & Pinheiro, D. (2014) · Mycopathologia · doi:10.1007/s11046-014-9730-z · Cited by 15
Scopulariopsis brevicaulis as the cause of dermatomycosis.
Petanović, M., Paradžik, M. T., Krištof, Ž., Cvitković, A., & Topolovac, Z. (2010) · PubMed · Cited by 15
Diffuse primary cutaneous infection by Alternaria alternata in a liver transplant recipient with pulmonary nocardiosis: Importance of prompt identification for clinical resolution
Campoli, C., Ferraro, S., Salfi, N. C. M., Coladonato, S., Morelli, M. C., Giannella, M., Ambretti, S., Viale, P., & Cricca, M. (2020) · Medical Mycology Case Reports · doi:10.1016/j.mmcr.2020.04.007 · Cited by 14
In Vitro Susceptibility of Environmental Isolates of Exophiala dermatitidis to Five Antifungal Drugs
Duarte, A. P. M., Pagnocca, F. C., Baron, N. C., Melhem, M. D. S. C., Palmeira, G. A., de Angelis, D. D. F., & Attili‐Angelis, D. (2012) · Mycopathologia · doi:10.1007/s11046-012-9597-9 · Cited by 14
Hyalohyphomycoses (Hyaline Moulds)
Torres, H. A., & Kontoyiannis, D. P. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6640-7_16 · Cited by 14
Treatment of cryptococcosis in the setting of HIV coinfection
Khawcharoenporn, T., Apisarnthanarak, A., & Mundy, L. M. (2007) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.5.6.1019 · Cited by 14
Non-Aspergillus Hyaline Molds: A Host-Based Perspective of Emerging Pathogenic Fungi Causing Sinopulmonary Diseases
Jacobs, S. E., & Walsh, T. J. (2023) · Journal of Fungi · doi:10.3390/jof9020212 · Cited by 13
The Importance of a Proper Aetiological Diagnosis in the Management of Patients with Invasive Mycoses: A Case Report of a Brain Abscess by Scedosporium apiospermum
Caggiano, G., Cantisani, P., Rolli, M., Gianfreda, C. D., Pizzolante, M., & Montagna, M. T. (2011) · Mycopathologia · doi:10.1007/s11046-011-9436-4 · Cited by 12
Scedosporium Apiospermum: Rare Cause of Brain Abscess in an Immunocompetent Patient
Deopujari, C. E., Sudke, A. Y., Shaikh, S. T., & Sakle, A. S. (2020) · Neurology India · doi:10.4103/0028-3886.293486 · Cited by 13
Fungal Keratitis: Recent Advances in Diagnosis and Treatment
Suman, S., Kumar, A., Saxena, I., & Kumar, M. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.98411 · Cited by 13
Molecular and MALDI‐ToF MS differentiation and antifungal susceptibility of prevalent clinical Fusarium species in China
Song, Y., Liu, X., Yang, Z., Meng, X., Xue, R., Yu, J., Al‐Hatmi, A. M. S., de Hoog, S., & Li, R. (2021) · Mycoses · doi:10.1111/myc.13345 · Cited by 13
Combination therapy for the treatment of pulmonary mold infections
McCarthy, M. W., Petraitis, V., & Walsh, T. J. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1325322 · Cited by 12
Antifúngicos en el tratamiento de las infecciones sistémicas: importancia del mecanismo de acción, espectro de actividad y resistencias
Cuenca‐Estrella, M. (2010) · Revista española de quimioterapia. Suplemento · Cited by 12
Self-citation
Invasive infection due to Saprochaete capitata in a young patient with hematological malignancies
de Carvalho, A. M. R., Neto, P. J. R., da Silva, C. M., Domingos, I. F., Gonçalves, S. S., Leite, E. P., de Morais, V. L. L., Macêdo, D. P. C., de Lima-Neto, R. G., & Neves, R. P. (2015) · Brazilian Journal of Microbiology · doi:10.1590/s1517-838246220120447 · Cited by 12
Molecular Barcoding of Microscopic Fungi with Emphasis on the Mucoralean Genera Mucor and Rhizopus
Gherbawy, Y. A. M. H., Kesselboth, C., Elhariry, H. M., & Hoffmann, K. (2010) · Springer eBooks · doi:10.1007/978-3-642-05042-8_11 · Cited by 12
Use of posaconazole in the treatment of invasive fungal infections
Mehta, A. K., & Langston, A. A. (2009) · Expert Review of Hematology · doi:10.1586/ehm.09.46 · Cited by 12
Anidulafungin and voriconazole in invasive fungal disease: pharmacological data and their use in combination
Perkhofer, S., & Lass‐Flörl, C. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903160658 · Cited by 12

Authors: Cuenca-Estrella, M., Gomez-Lopez, A., Mellado, E., Buitrago, M. J., Monzon, A., & Rodriguez-Tudela, J. L.
Affiliations: Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain
Instituto de Salud Carlos III (ES)
ORCID: Mellado, Emilia
Venue: Antimicrobial Agents and Chemotherapy
Publisher: American Society for Microbiology
Published: 2006-03
Volume: 50
Issue: 3
Pages: 917-921
ISSN: 0066-4804 (ISSN-L)
1098-6596
DOI: 10.1128/aac.50.3.917-921.2006
PMC: PMC1426453
OpenAlex: W2160917189
Cited by: 298
References: 32
Citations by year: 2026: 5 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 9 · 2020: 11 · 2019: 3 · 2018: 8 · 2017: 10 · 2016: 12 · 2015: 10 · 2014: 20 · 2013: 14 · 2012: 9
FWCI: 23.42
Type: journal article
Language: en
Open access: green
europepmc.org
Licence: journals.asm.org/non-commercial-tdm-license (tdm)
Locations: Antimicrobial Agents and Chemotherapy (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Keywords: posaconazole, antifungal agents, clinical fungal isolates, Candida, Aspergillus, filamentous fungi, antifungal susceptibility, minimum inhibitory concentration, voriconazole resistance, caspofungin, amphotericin B, fluconazole resistance, itraconazole, Cryptococcus neoformans, Scedosporium prolificans, Scedosporium apiospermum, Paecilomyces, Penicillium, Mucorales, black fungus, Spanish isolates
MeSH terms: Caspofungin, Amphotericin B, Antifungal Agents, Flucytosine, Fungi, Humans, Microbial Sensitivity Tests, Mycoses, Peptides, Cyclic, Pyrimidines, Spain, Triazoles, Yeasts, Fluconazole, Itraconazole, Echinocandins, Lipopeptides, Voriconazole

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Head-to-Head Comparison of the Activities of Currently Available Antifungal Agents against 3,378 Spanish Clinical Isolates of Yeasts and Filamentous Fungi

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks